30-05-2025
Mizuho Securities Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP)
In a report released on May 20, Salim Syed from Mizuho Securities maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report), with a price target of $85.00. The company's shares opened today at $37.00.
Confident Investing Starts Here:
Syed covers the Healthcare sector, focusing on stocks such as Vaxcyte, Wave Life Sciences, and Cytokinetics. According to TipRanks, Syed has an average return of -9.6% and a 35.89% success rate on recommended stocks.
Currently, the analyst consensus on Crispr Therapeutics AG is a Moderate Buy with an average price target of $67.63, an 82.78% upside from current levels. In a report released yesterday, Citizens JMP also reiterated a Buy rating on the stock with a $86.00 price target.
CRSP market cap is currently $3.39B and has a P/E ratio of -8.19.
Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CRSP in relation to earlier this year. Most recently, in February 2025, John Greene, a Director at CRSP bought 7,000.00 shares for a total of $313,880.00.
